Skip to search formSkip to main contentSkip to account menu

volasertib

Known as: Benzamide, N-(Trans-4-(4-(Cyclopropylmethyl)-1-Piperazinyl)Cyclohexyl)-4-(((7r)-7-Ethyl-5,6,7,8-Tetrahydro-5-Methyl-8-(1-Methylethyl)-6-Oxo-2-Pteridinyl)Amino)-3-Methoxy-, Polo-like Kinase 1 Inhibitor BI 6727 
A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

BI 6727
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
Background Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the… 
2018
2018
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
BackgroundVolasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve… 
2017
2017
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
Volasertib, a selective PLK1 inhibitor, was effective for acute myeloid leukemia (AML) patients in clinical trials. However, its… 
2017
2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
Elderly and frail patients, diagnosed with acute myeloid leukemia (AML) and ineligible to undergo intensive treatment, have a… 
2016
2016
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors
SummaryPurpose This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and clinical effects of… 
2014
2014
Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
In a search for novel agents that boost the anti-neoplastic effects of polo-like kinase 1 (PLK1) inhibitor volasertib, we found… 
2013
2013
Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC).
5504 Background: Volasertib (V) is a potent and selective cell cycle kinase inhibitor that induces mitotic arrest and apoptosis… 
2012
2012
Abstract 3725: Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Purpose: Patients with advanced urothelial… 
2011
2011
Phase II study of single-agent volasertib (BI 6727) for second-line treatment of urothelial cancer (UC).
253 Background: Polo-like kinase 1 (Plk1) controls multiple essential steps of mitosis. Volasertib (BI 6727) is a first-in-class… 
2010
2010
Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination…
Abstract 3316 Background: Patients with refractory or relapsed AML have a poor prognosis and new treatments are needed for this… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)